BRIM Biotechnology, Inc. raises $20 million in Series E funding round

Taipei, Taiwan, 1st December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding…

Download BRIM's Corporate Overview